Structural Formula For Clopidogrel Bisulfate (90c2699c Bee5 48a3 Bfda 478d66c5a261 01)
Clopidogrel
Product Images NDC 53808-1025
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 53808-1025). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by State Of Florida Doh Central Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (90c2699c Bee5 48a3 Bfda 478d66c5a261 02)
Figure 2 (90c2699c Bee5 48a3 Bfda 478d66c5a261 03)
This is a comparison of cumulative event rates (%) for cardiovascular death, myocardial infarction, and stroke between two groups: placebo (+ aspirin) and clopidogrel (+ aspirin). The study was conducted for several months and other standard therapies were used as appropriate. The p-value was 000008, indicating a statistically significant difference between the two groups. No other useful information is available due to the low-quality output.*
Figure 3 (90c2699c Bee5 48a3 Bfda 478d66c5a261 04)
Figure 3: Cumulative Event Rates For Death In The Commit Study (90c2699c Bee5 48a3 Bfda 478d66c5a261 05)
The text describes data related to the number of deaths that occurred before the first discharge in a medical trial between two groups of patients: those who were given placebo and those who were given a drug called Clopidogrel. The percentage of deaths in the group that took placebo was 3.1% while the percentage of deaths in the group that took Clopidogrel was 7.5%. The results show a 7% reduction in risk for the group that took Clopidogrel with a p-value of 0.03. The data was collected up to 28 days after randomization.*
Figure 5 (90c2699c Bee5 48a3 Bfda 478d66c5a261 06)
This is a report showing the comparison of the effects of Placebo and Clopidogrel on patients with certain medical conditions. The number of patients experiencing events for both groups is given along with the proportional risk percentage. There is also mention of significant reduction in reinfarction, death and stroke. The time period considered is up to 28 days since randomization.*
Figure 6 (90c2699c Bee5 48a3 Bfda 478d66c5a261 07)
This appears to be a table or chart without context or explanation, and is not available for useful description.*
Figure 7 (90c2699c Bee5 48a3 Bfda 478d66c5a261 08)
This text presents data on a study evaluating the effects of Clopidogrel versus Placebo on various factors such as previous MI, Killip class, and infarct location. The study found that Clopidogrel was better than Placebo in reducing events, with a p-value of 0.002. Odds ratios and confidence intervals are also provided. Heterogeneity was tested and reported.*
Figure 8 (90c2699c Bee5 48a3 Bfda 478d66c5a261 09)
The figure displays the cumulative event rate of fatal or non-fatal vascular events for Aspirin and Clopidogrel treatment. The months of follow-up are not clearly visible. The statistical significance of the difference between the two treatment options is shown as P=0.045.*
Label Image For 75mg (Clopidogrel 75mg)
This is a description of a medicine called Clopidogrel, which comes in 75mg tablets packed in a bottle containing 30 tablets. The manufacturer of the medication is Teva, and it has a lot number of 0124 21400. The expiry date of the medication is 07-24-2014. It was packaged by the DOH Central Pharmacy in Talahasses, FL 32304. The UPC number for the medicine is 300837314059.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
